Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 FY25 Earnings Call

ARCLIS growth remains strong, while KPL-387 offers a later expansion opportunity.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-24
Length31 minutes
EPS$0.17
EPS consensus$0.29
Revenue$202.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All KNSA earnings ยท Back to KNSA overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.